

North America Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class (Beta Blockers, Alpha Adrenergic Agonists, Prostaglandins Analogues, Carbonic Anhydrase Inhibitors, Combination Drugs, and Others), Indication (Open Angle Glaucoma, Angle Closure Glaucoma, and Others), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)

<https://marketpublishers.com/r/N5053BF334B8EN.html>

Date: April 2025

Pages: 132

Price: US\$ 3,450.00 (Single User License)

ID: N5053BF334B8EN

Abstracts

The North America glaucoma therapeutics market was valued at US\$ 2,634.52 million in 2023 and is expected to reach US\$ 3,421.64 million by 2031; it is estimated to register a CAGR of 3.3% from 2023 to 2031.

Mounting Incidence of Glaucoma Disease Fuels North America Glaucoma Therapeutics Market

Glaucoma is an eye disorder caused due to the damaged optic nerve, which can eventually lead to total blindness. Glaucoma patients may experience a gradual loss of nerve tissue, resulting in vision impairment or blindness if left untreated. Glaucoma cases are increasing significantly across the world. As per the Glaucoma Research Foundation, an estimated 22 million people worldwide would attain blindness due to glaucoma by 2040. Further, Glaucoma is a leading cause of blindness worldwide, affecting over 60 million people and leading to approximately 4.5 million cases of blindness, according to the World Health Organization. According to estimates provided in an article published in the Association for Research in Vision and Ophthalmology (ARVO) Journal in January 2021, the number of people suffering from glaucoma in

Mexico would reach 2.5 million, 3 million, and 3.4 million by the end of 2030, 2040, and 2050, respectively. The demand for glaucoma treatments is increasing with the rising number of glaucoma cases in the global population. Medical and surgical procedures meant to manage this disease focus on lowering intraocular pressure (IOP). Prostaglandin analogs are among the drugs widely recommended for effectively reducing IOP by promoting better drainage from the eye. These products have been mainstream glaucoma treatment due to their efficacy and limited adverse effects.

North America Glaucoma Therapeutics Market Overview

As per the Population Reference Bureau 2019, the number of individuals aged 65 and above in the US is estimated to double from 52 million (16% of the total population) in 2018 to nearly 95 million (23% of the total population) by 2060. A study conducted by the American Academy of Ophthalmology in 2019 states that nearly 7.32 million people aged 70-75 is estimated to be affected by primary open-angle glaucoma (POAG) in the US by 2050. Thus, the glaucoma therapeutics market growth in the US is primarily driven by the increasing prevalence of eye diseases, especially in the geriatric population. The US accounts for the largest share of the glaucoma therapeutics market in North America.

Various organic and inorganic growth strategies adopted by market players also contribute notably to the glaucoma therapeutics market progress in the US. A few of such growth strategies are mentioned below.

In October 2023, Stuart Therapeutics and Glaukos signed a license agreement for Stuart Therapeutics' ST-113 drug candidate designed for neuroprotection in glaucoma. In August 2022, Alcon acquired Aerie Pharmaceuticals, Inc. This transaction confirms Alcon's commitment to the ophthalmic pharmaceutical space, and it is expected to enhance its existing commercial expertise by adding broader pharmaceutical R&D capabilities, thereby maximizing the value of its diversified portfolio. North America Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US\$ Million)

North America Glaucoma Therapeutics Market Segmentation

The North America glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.

Based on drug class, the North America glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic

anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.

In terms of indication, the North America glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.

By distribution channel, the North America glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.

By country, the North America glaucoma therapeutics market is segmented into the US, Canada, and Mexico. The US dominated the North America glaucoma therapeutics market share in 2023.

Alcon AG, AbbVie Inc, Bausch & Lomb Inc, Fera Pharmaceuticals, LLC, Viatrix Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the North America glaucoma therapeutics market.

Reason to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America glaucoma therapeutics market.

Highlights key business priorities to assist companies to realign their business strategies.

The key findings and recommendations highlight crucial progressive industry trends in the North America glaucoma therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.

Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America glaucoma therapeutics market, as well as those hindering it.

Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

The List of Companies - North America Glaucoma Therapeutics Market

Alcon AG

AbbVie Inc

Bausch & Lomb Inc

Fera Pharmaceuticals, LLC

Viartis Inc

Novartis AG

Sun Pharmaceutical Industries Ltd

Teva Pharmaceuticals Industries Ltd

Thea Pharma Inc

Santen Pharmaceutical Co., Ltd

Contents

1. INTRODUCTION

- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation

2. EXECUTIVE SUMMARY

- 2.1 Key Insights
- 2.2 Market Attractiveness

3. RESEARCH METHODOLOGY

- 3.1 Secondary Research
- 3.2 Primary Research
 - 3.2.1 Hypothesis formulation:
 - 3.2.2 Macro-economic factor analysis:
 - 3.2.3 Developing base number:
 - 3.2.4 Data Triangulation:
 - 3.2.5 Country level data:

4. NORTH AMERICA GLAUCOMA THERAPEUTICS MARKET LANDSCAPE

- 4.1 Overview
- 4.2 PEST Analysis

5. NORTH AMERICA GLAUCOMA THERAPEUTICS MARKET - KEY MARKET DYNAMICS

- 5.1 Market Drivers
 - 5.1.1 Mounting Incidence of Glaucoma Disease
 - 5.1.2 Increasing Number of Product Launches, Collaborations, and Acquisitions
- 5.2 Market Restraints
 - 5.2.1 Medication Regimen Compliance Issues
- 5.3 Market Opportunities
 - 5.3.1 Development of Wearable Technologies
- 5.4 Future Trends
 - 5.4.1 Development of Novel Drug Delivery Methods

5.5 Impact of Drivers and Restraints:

6. GLAUCOMA THERAPEUTICS MARKET - NORTH AMERICA ANALYSIS

6.1 Glaucoma Therapeutics Market Revenue (US\$ Million), 2021-2031

6.2 Glaucoma Therapeutics Market Forecast Analysis

7. NORTH AMERICA GLAUCOMA THERAPEUTICS MARKET ANALYSIS - BY DRUG CLASS

7.1 Beta Blockers

7.1.1 Overview

7.1.2 Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

7.2 Alpha Adrenergic Agonists

7.2.1 Overview

7.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

7.3 Prostaglandins Analogues

7.3.1 Overview

7.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

7.4 Carbonic Anhydrase Inhibitors

7.4.1 Overview

7.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

7.5 Combination Drugs

7.5.1 Overview

7.5.2 Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

7.6 Others

7.6.1 Overview

7.6.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

8. NORTH AMERICA GLAUCOMA THERAPEUTICS MARKET ANALYSIS - BY INDICATION

8.1 Open Angle Glaucoma

8.1.1 Overview

8.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

8.2 Angle Closure Glaucoma

8.2.1 Overview

8.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

8.3 Others

8.3.1 Overview

8.3.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

9. NORTH AMERICA GLAUCOMA THERAPEUTICS MARKET ANALYSIS - BY DISTRIBUTION CHANNEL

9.1 Hospital Pharmacy

9.1.1 Overview

9.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

9.2 Retail Pharmacy

9.2.1 Overview

9.2.2 Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

9.3 Online Pharmacy

9.3.1 Overview

9.3.2 Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

10. NORTH AMERICA GLAUCOMA THERAPEUTICS MARKET - COUNTRY ANALYSIS

10.1 North America

10.1.1 North America: Glaucoma Therapeutics Market Breakdown, by Key Country, 2023 and 2031 (%)

10.1.1.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country

10.1.1.2 United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

10.1.1.2.1 United States: Glaucoma Therapeutics Market Breakdown, by Drug

Class

10.1.1.2.2 United States: Glaucoma Therapeutics Market Breakdown, by Indication

10.1.1.2.3 United States: Glaucoma Therapeutics Market Breakdown, by

Distribution Channel

10.1.1.3 Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031
(US\$ Million)

10.1.1.3.1 Canada: Glaucoma Therapeutics Market Breakdown, by Drug Class

10.1.1.3.2 Canada: Glaucoma Therapeutics Market Breakdown, by Indication

10.1.1.3.3 Canada: Glaucoma Therapeutics Market Breakdown, by Distribution

Channel

10.1.1.4 Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031
(US\$ Million)

10.1.1.4.1 Mexico: Glaucoma Therapeutics Market Breakdown, by Drug Class

10.1.1.4.2 Mexico: Glaucoma Therapeutics Market Breakdown, by Indication

10.1.1.4.3 Mexico: Glaucoma Therapeutics Market Breakdown, by Distribution

Channel

11. GLAUCOMA THERAPEUTICS MARKET - INDUSTRY LANDSCAPE

11.1 Growth Strategies in Glaucoma Therapeutics Market

11.2 Organic Growth Strategies

11.2.1 Overview

11.3 Inorganic Growth Strategies

11.3.1 Overview

12. COMPANY PROFILES

12.1 Alcon AG

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 AbbVie Inc

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
- 12.3 Bausch & Lomb Inc
 - 12.3.1 Key Facts
 - 12.3.2 Business Description
 - 12.3.3 Products and Services
 - 12.3.4 Financial Overview
 - 12.3.5 SWOT Analysis
 - 12.3.6 Key Developments
- 12.4 Fera Pharmaceuticals, LLC
 - 12.4.1 Key Facts
 - 12.4.2 Business Description
 - 12.4.3 Products and Services
 - 12.4.4 Financial Overview
 - 12.4.5 SWOT Analysis
 - 12.4.6 Key Developments
- 12.5 Viatris Inc
 - 12.5.1 Key Facts
 - 12.5.2 Business Description
 - 12.5.3 Products and Services
 - 12.5.4 Financial Overview
 - 12.5.5 SWOT Analysis
 - 12.5.6 Key Developments
- 12.6 Novartis AG
 - 12.6.1 Key Facts
 - 12.6.2 Business Description
 - 12.6.3 Products and Services
 - 12.6.4 Financial Overview
 - 12.6.5 SWOT Analysis
 - 12.6.6 Key Developments
- 12.7 Sun Pharmaceutical Industries Ltd
 - 12.7.1 Key Facts
 - 12.7.2 Business Description
 - 12.7.3 Products and Services
 - 12.7.4 Financial Overview
 - 12.7.5 SWOT Analysis
 - 12.7.6 Key Developments
- 12.8 Teva Pharmaceutical Industries Ltd
 - 12.8.1 Key Facts

- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
- 12.9 Thea Pharma Inc
 - 12.9.1 Key Facts
 - 12.9.2 Business Description
 - 12.9.3 Products and Services
 - 12.9.4 Financial Overview
 - 12.9.5 SWOT Analysis
 - 12.9.6 Key Developments
- 12.10 Santen Pharmaceutical Co., Ltd.
 - 12.10.1 Key Facts
 - 12.10.2 Business Description
 - 12.10.3 Products and Services
 - 12.10.4 Financial Overview
 - 12.10.5 SWOT Analysis
 - 12.10.6 Key Developments

13. APPENDIX

- 13.1 About The Insight Partners
- 13.2 Glossary of Terms

List Of Tables

LIST OF TABLES

Table 1. North America Glaucoma Therapeutics Market Segmentation

Table 2. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

Table 3. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)
- by Drug Class

Table 4. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)
- by Indication

Table 5. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)
- by Distribution Channel

Table 6. North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million) - by Country

Table 7. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million) - by Drug Class

Table 8. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million) - by Indication

Table 9. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million) - by Distribution Channel

Table 10. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million) - by Drug Class

Table 11. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million) - by Indication

Table 12. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million) - by Distribution Channel

Table 13. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million) - by Drug Class

Table 14. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million) - by Indication

Table 15. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million) - by Distribution Channel

Table 16. Recent Organic Growth Strategies in Glaucoma Therapeutics Market

Table 17. Recent Inorganic Growth Strategies in the Glaucoma Therapeutics Market

Table 18. Glossary of Terms

List Of Figures

LIST OF FIGURES

Figure 1. North America Glaucoma Therapeutics Market Segmentation, by Country

Figure 2. PEST Analysis

Figure 3. Glaucoma Therapeutics Market - Key Market Dynamics

Figure 4. Impact Analysis of Drivers and Restraints

Figure 5. Glaucoma Therapeutics Market Revenue (US\$ Million), 2021-2031

Figure 6. Glaucoma Therapeutics Market Share (%) - by Drug Class (2023 and 2031)

Figure 7. Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

Figure 8. Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

Figure 9. Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

Figure 10. Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

Figure 11. Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

Figure 12. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

Figure 13. Glaucoma Therapeutics Market Share (%) - by Indication (2023 and 2031)

Figure 14. Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

Figure 15. Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

Figure 16. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

Figure 17. Glaucoma Therapeutics Market Share (%) - by Distribution Channel (2023 and 2031)

Figure 18. Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

Figure 19. Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

Figure 20. Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

Figure 21. North America Glaucoma Therapeutics Market, by Key Country - Revenue (2023) (US\$ Million)

Figure 22. North America: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)

Figure 23. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

Figure 24. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

Figure 25. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US\$ Million)

Figure 26. Growth Strategies in Glaucoma Therapeutics Market

I would like to order

Product name: North America Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class (Beta Blockers, Alpha Adrenergic Agonists, Prostaglandins Analogues, Carbonic Anhydrase Inhibitors, Combination Drugs, and Others), Indication (Open Angle Glaucoma, Angle Closure Glaucoma, and Others), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)

Product link: <https://marketpublishers.com/r/N5053BF334B8EN.html>

Price: US\$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N5053BF334B8EN.html>